Fig. 2From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckPFS by PD-L1 expression. a From start of first-line chemotherapy (n = 242) and b second-line chemotherapy (n = 83)Back to article page